Weekly Digest – March 2026 Weekly Digest – March 2026 27 February 2026: WuXi XDC enters strategic collaboration with Earendil Labs on WuXiTecan-2 payload-linker technology platform WuXi XDC has announced a strategic collaboration with Earendil Labs to advance next-generation antibody-drug […]
Weekly Digest – March 2026 Weekly Digest – March 2026 27 February 2026: Ligachem Bio and Ono Pharmaceutical accelerate joint ADC research, receiving follow-up milestones Ligachem Biosciences has announced that it will receive additional development milestone payments from Ono Pharmaceutical […]
Weekly Digest – February 2026 Weekly Digest – February 2026 24 February 2026: Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189, a nectin-4 miniprotein radioconjugate Aktis Oncology announced that the U.S. FDA has granted Fast Track designation to […]
Weekly Digest – February 2026 Weekly Digest – February 2026 25 February 2026: Kivu Bioscience announced HREC approval and Clinical Trial Notification (CTN) clearance in Australia to initiate a first-in-human clinical trial for KIVU-305 Kivu Bioscience announced new preclinical data […]
Weekly Digest – February 2026 Weekly Digest – February 2026 24 February 2026: Bispecific ADC Iza-bren meets both primary endpoints, significantly improving PFS and OS in unresectable or advanced/metastatic triple-negative breast cancer post-taxane failure Sichuan Baili Tianheng Pharmaceutical announced that […]
Weekly Digest – February 2026 Weekly Digest – February 2026 25 February 2026: IDEAYA Biosciences announces first-patient-in for Phase 1 trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific TOP1 ADC IDEAYA Biosciences announced that the first patient has been enrolled […]
Weekly Digest – February 2026 Weekly Digest – February 2026 26 February 2026: Molecular partners signs development agreement with Eckert & Ziegler for targeted alpha radiotherapeutics Molecular Partners announced a development agreement with Eckert & Ziegler to support the advancement […]
Weekly Digest – February 2026 Weekly Digest – February 2026 24 February 2026: Ligachem Biosciences expands ADC pipeline with new NovaRock antibody license LigaChem Biosciences announced that it has signed a new technology licensing agreement with U.S.-based NovaRock Biotherapeutics to […]
Weekly Digest – February 2026 Weekly Digest – February 2026 16 February 2026: Novartis Pluvicto (lutetium (177Lu) vipivotide tetraxetan) receives MHRA authorisation for new indication for eligible patients with PSMA‑positive metastatic castration‑resistant prostate cancer Novartis announced that the UK Medicines […]
Weekly Digest – February 2026 Weekly Digest – February 2026 19 February 2026: ENHERTU Type II Variation Application validated in the EU as post-neoadjuvant treatment for patients with HER2 positive early breast cancer The European Medicines Agency has validated a […]
